Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637866 | 1.00 | PRKCZ (0.50) | PRKCZROCK1ROCK2CCR2RECQL | |
| SCHEMBL5641678 | 0.91 | HTR2C (0.48) | PRKCZROCK1ROCK2CCR2HTR2C | |
| SCHEMBL5638069 | 0.90 | PRKCZ (0.49) | PRKCZROCK1HTR2CHTR2BCHRNB2 | |
| SCHEMBL5640513 | 0.89 | PRKCZ (0.48) | PRKCZROCK1HRH1HTR2CHTR2B | |
| SCHEMBL5640512 | 0.88 | PRKCZ (0.47) | PRKCZROCK1CHRNB2CHRNA4 | |
| SCHEMBL6494468 | 0.77 | PRKCZ (0.48) | PRKCZROCK1ROCK2CHRNB2CHRNA4 | |
| SCHEMBL30918017 | 0.75 | RECQL (0.60) | RECQLKDM4CHTR2CHTR2B | |
| SCHEMBL17602220 | 0.75 | RECQL (0.60) | RECQLKDM4CHTR2CHTR2B | |
| SCHEMBL19023339 | 0.71 | IKBKB (0.45) | PRKCZROCK1ROCK2HRH1 | |
| SCHEMBL870390 | 0.70 | RECQL (0.66) | RECQLKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | PRKCZ 171/4885ROCK1 2/4885ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.